YESENIA AGUILA: Open Payments
NPI 1245966092 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$702 in 30 payments from 9 companies in 2025. Trend: 2023 $248 · 2024 $474 · 2025 $702
Food & beverage: $702
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $199 |
| Novo Nordisk Inc | 4 | $180 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $95 |
| Madrigal Pharmaceuticals | 2 | $89 |
| Braintree Laboratories, Inc. | 2 | $40 |
| Ardelyx, Inc. | 2 | $32 |
| Celltrion USA Inc. | 1 | $29 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $22 |
| Janssen Biotech, Inc. | 1 | $18 |
Products named: Wegovy, RINVOQ, REZDIFFRA, ENTYVIO, MAVYRET, IBSRELA, EOHILIA, VEGZELMA.
Industry payments across CA — which companies pay providers there.
